Alzheimer’s disease (AD) is the most common form of dementia and increasing evidence has shown that neuroinflammation is an important and early hallmark of the pathogenesis. It has been suggested that tumor necrosis factor (TNF), a pro-inflammatory cytokine, might be detrimental in AD, though the results coming from clinical trials on anti-TNF inhibitors are inconclusive. Prof. Roosmarijn Vandenbroucke (VIB-UGent) reports in the authorative journal EMBO Molecular Medicine that TNF, via activation of its receptor TNFR1, is the main inflammatory upstream mediator of the AD-associated changes at the choroid plexus and that targeting TNF/TNFR1 signaling has therapeutic potential.
MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), today announced financial results for the financial year ended December 31, 2017 and provided an update on its strategic outlook.
Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced its financial results for the year ended 31st December 2017, which have been prepared in accordance with IFRS as issued by the IASB and adopted by the European Union, business highlights year-to-date and the outlook for the remainder of the year.
Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek, kondigt vandaag aan een live webcastconferentie op te zetten op donderdag 1 maart 2018 om 14:00 CET / 13:00 BST (VK) / 08:00 EDT (VS) om zijn 2017 resultaten en 2018 vooruitzichten aan te kondigen.
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, March 1, 2018 at 3:00 pm CET (9:00 am ET) to discuss its 2017 financial results and provide a fourth quarter business update
Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.
Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.
Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.
The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.
Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.
VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.
imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.
Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes.